Navigation Links
ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
Date:8/14/2008

BROOMFIELD, Colo., Aug. 14 /PRNewswire/ -- ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that it has appointed William R. Hiatt, MD, as Director of Clinical and Regulatory Strategy. In this newly created position, Dr. Hiatt will be responsible for developing strategic regulatory and clinical initiatives designed to support the company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator in late-stage development for heart failure, as well as other compounds in ARCA's pipeline.

"Dr. Hiatt is a recognized expert who knows cardiovascular medicine from virtually every angle: as researcher, physician, educator, clinician and former advisor to the U.S. Food and Drug Administration," said Richard B. Brewer, president and chief executive officer of ARCA biopharma. "He brings valuable experience and insight to ARCA as we prepare to introduce our first product and begin to educate the medical community about the benefits of genetically targeted treatment of heart failure."

"I look forward to working with the talented men and women at ARCA to bring important new solutions to heart failure patients," said Dr. William Hiatt. "By inaugurating the personalized medicine trail in the heart failure arena, ARCA is changing the way we offer treatment to patients with this serious chronic condition."

Dr. Hiatt is Professor of Medicine, Professor of Cardiovascular Research and Chief of the Section of Vascular Medicine at the University of Colorado Denver's Anschutz Medical Campus. Throughout his career, Dr. Hiatt's research has focused on developing new therapies for patients with peripheral arterial disease and understanding its pathophysiology in terms of the effects of muscle ischemia on muscle metabolism and function. Dr. Hiatt also is President of the Colorado Prevention Center, a non-profit medical research and disease prevention center affiliated with the university that promotes disease prevention through clinical trials and outreach programs. In addition, Dr. Hiatt served on the FDA Cardiovascular and Renal Advisory Committee from 2003 until 2008, and was Chairman of the Cardiovascular and Renal Drugs Committee from January 2006 to June 2008.

Dr. Hiatt received his medical degree cum laude from the University of Colorado School of Medicine; he completed his residence at Boston University Hospital and the University of Colorado Health Sciences Center in 1979. He completed a fellowship in internal medicine and vascular medicine at the University of Colorado in 1981. He is Past President of the Society for Vascular Medicine and Biology and serves as an advisor to the Board of the International Union of Angiology.

About ARCA biopharma

ARCA biopharma, Inc. is a privately held company focused on developing and commercializing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product, Gencaro(TM) (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that predict individual patient response to Gencaro. The company plans to file a New Drug Application with the U.S. Food and Drug Administration during the summer of 2008 for approval of Gencaro for the treatment of heart failure. The companion genetic test for Gencaro is in development by ARCA's partner, Laboratory Corporation of America. If approved, Gencaro could become the first genetically personalized cardiovascular therapy. For more information please visit http://www.arcabiopharma.com.


'/>"/>
SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ondine Biopharma Announces Second Quarter 2008 Financial Results
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
5. ARCA biopharma Appoints James Carr as Vice President of Marketing
6. TriCipher is First to Transfer Smart Card Level Security to Federally Approved SAFE-BioPharma(TM) Roaming Credentials
7. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
8. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
9. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
10. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
11. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Sequenom, Inc. (NASDAQ: SQNM ... lives through the development of innovative products and services, ... the United States denied its petition to ... of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are ... by the Supreme Court,s Mayo Collaborative Services v. Prometheus ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):